Anvesana
APPROACH: RNA-sequence target identification
STRATEGIC AREA: ASO (Anti-sense Oligonucleotide) therapeutics for bleeding disorder
P2C FUNDING IMPACT: Factor XI deficiency and women with Hemophilia
 
Afimmune
APPROACH: Synthetic fatty acid small molecule
STRATEGIC AREA: Oral small molecule for treatment of inheritable blood disorders
P2C FUNDING IMPACT: Treatment of Sickle Cell Disease and Thalassemia
 
 
Be Biopharma
APPROACH: Engineered B-cells as a novel approach to cellular medicine
STRATEGIC AREA: Engineered B-cell medicine for the treatment of inheritable bleeding disorders
P2C FUNDING IMPACT: Treatment of bleeding disorders including Hemophilia B
 
Spark Biomedical
APPROACH: Non-invasive vagus nerve stimulation
STRATEGIC AREA: Non-invasive medical device
P2C FUNDING IMPACT: Von Willebrand Disease and women with Heavy Menstrual Bleeding
 
Seawolf Therapeutics
APPROACH: Non-viral mediated platform for genetic medicines designed to be durable and redosable
STRATEGIC AREA: Non-viral mediated DNA delivery genetic medicines for inheritable diseases including bleeding disorders
P2C FUNDING IMPACT: Treatment of bleeding disorders including Hemophilia A & B with potential for additional rare bleeding disorders
SeraGene Therapeutics
APPROACH: RNA technology targeting and controlling proteins involved in clotting
STRATEGIC AREA: Long-lasting therapies that reduce the burden of treatment by precisely modulating the body’s natural clotting proteins to restore normal blood function across several different bleeding disorders
P2C FUNDING IMPACT: Treatment of bleeding disorders including VWD with a focus on women’s health